Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027947 (
neutropenia
)
17,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t
1/2
), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (C
max
) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for
neutropenia
and diarrhea in 353 patients. PK-efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN-38 (uSN38) above a threshold and higher C
avg
of tIRI, tSN38, and uSN38.
Neutropenia
was associated with uSN38 C
max
and diarrhea with tIRI C
max
. Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal-IRI dose of 70 mg/m
2
(free-base; equivalent to 80 mg/m
2
salt
base) Q2W over 100 mg/m
2
Q3W.
...
PMID:Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. 2844 10
<< Previous
1
2
